{"id":11192,"date":"2021-05-28T00:00:00","date_gmt":"2021-05-28T05:00:00","guid":{"rendered":"https:\/\/myeloma.ca\/1970\/01\/01\/pomalyst-pomalidomide-et-thalomid-thalidomide-evaluation-du-risque-potentiel-de-leucoencephalopathie-multifocale-progressive\/"},"modified":"2025-08-19T08:28:17","modified_gmt":"2025-08-19T13:28:17","slug":"pomalyst-pomalidomide-et-thalomid-thalidomide-evaluation-du-risque-potentiel-de-leucoencephalopathie-multifocale-progressive","status":"publish","type":"post","link":"https:\/\/myeloma.ca\/fr\/2021\/05\/28\/pomalyst-pomalidomide-et-thalomid-thalidomide-evaluation-du-risque-potentiel-de-leucoencephalopathie-multifocale-progressive\/","title":{"rendered":"POMALYST (POMALIDOMIDE) ET THALOMID (THALIDOMIDE) &#8211; \u00c9VALUATION DU RISQUE POTENTIEL DE LEUCOENC\u00c9PHALOPATHIE MULTIFOCALE PROGRESSIVE"},"content":{"rendered":"<p><a href=\"\/pixms\/uploads\/serve\/ckeditor\/fr_21_106578_783_stakeholders_notification_pomalidomide_and_thalidomide_pml-2.pdf\" target=\"_blank\" rel=\"noopener\">Un r\u00e9sum\u00e9 de l\u2019examen de l\u2019innocuit\u00e9 (REI) concernant Pomalyst (pomalidomide) et Thalomid (thalidomide) et le risque potentiel de leucoenc\u00e9phalopathie multifocale progressive (LEMP) a \u00e9t\u00e9 publi\u00e9 par Sant\u00e9 Canada.<\/a> Le but du REI est de permettre \u00e0 la population canadienne d\u2019avoir une compr\u00e9hension suffisante de l\u2019examen de l\u2019innocuit\u00e9 qui a \u00e9t\u00e9 men\u00e9 par Sant\u00e9 Canada, plus pr\u00e9cis\u00e9ment, ce qui a \u00e9t\u00e9 \u00e9valu\u00e9 et constat\u00e9, ainsi que les mesures qui ont \u00e9t\u00e9 prises.&nbsp;\u00bb<\/p>\n<p><a href=\"\/pixms\/uploads\/serve\/ckeditor\/fr_ssr_pomalidomide_and_thalidomide_pml_final.pdf\" target=\"_blank\" rel=\"noopener\">Lire le r\u00e9sum\u00e9 de l\u2019examen de l\u2019innocuit\u00e9 (REI)<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Un r\u00e9sum\u00e9 de l\u2019examen de l\u2019innocuit\u00e9 (REI) concernant Pomalyst (pomalidomide) et Thalomid (thalidomide) et le risque potentiel de leucoenc\u00e9phalopathie multifocale progressive (LEMP) a \u00e9t\u00e9 publi\u00e9 par Sant\u00e9 Canada. Le but du REI est de permettre \u00e0 la population canadienne d\u2019avoir une compr\u00e9hension suffisante de l\u2019examen de l\u2019innocuit\u00e9 qui a \u00e9t\u00e9 men\u00e9 par Sant\u00e9 Canada, plus [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_members_access_role":[],"_members_access_error":""},"categories":[53,53,58,58],"tags":[],"class_list":["post-11192","post","type-post","status-publish","format-standard","hentry","category-actualites-et-evenement","category-nouvelles-de-myelome-canada"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 5.0.1.1 - aioseo.com -->\n\t<meta name=\"description\" content=\"Un r\u00e9sum\u00e9 de l\u2019examen de l\u2019innocuit\u00e9 (REI) concernant Pomalyst (pomalidomide) et Thalomid (thalidomide) et le risque potentiel de leucoenc\u00e9phalopathie multifocale progressive (LEMP) a \u00e9t\u00e9 publi\u00e9 par Sant\u00e9 Canada. Le but du REI est de permettre \u00e0 la population canadienne d\u2019avoir une compr\u00e9hension suffisante de l\u2019examen de l\u2019innocuit\u00e9 qui a \u00e9t\u00e9 men\u00e9 par Sant\u00e9 Canada, plus\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"lemieuxbedard\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/myeloma.ca\/fr\/2021\/05\/28\/pomalyst-pomalidomide-et-thalomid-thalidomide-evaluation-du-risque-potentiel-de-leucoencephalopathie-multifocale-progressive\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.1.1\" \/>\n\t\t<meta property=\"og:locale\" content=\"fr_FR\" \/>\n\t\t<meta property=\"og:site_name\" content=\"My\u00e9lome Canada |\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"POMALYST (POMALIDOMIDE) ET THALOMID (THALIDOMIDE) \u2013 \u00c9VALUATION DU RISQUE POTENTIEL DE LEUCOENC\u00c9PHALOPATHIE MULTIFOCALE PROGRESSIVE | My\u00e9lome Canada\" \/>\n\t\t<meta property=\"og:description\" content=\"Un r\u00e9sum\u00e9 de l\u2019examen de l\u2019innocuit\u00e9 (REI) concernant Pomalyst (pomalidomide) et Thalomid (thalidomide) et le risque potentiel de leucoenc\u00e9phalopathie multifocale progressive (LEMP) a \u00e9t\u00e9 publi\u00e9 par Sant\u00e9 Canada. Le but du REI est de permettre \u00e0 la population canadienne d\u2019avoir une compr\u00e9hension suffisante de l\u2019examen de l\u2019innocuit\u00e9 qui a \u00e9t\u00e9 men\u00e9 par Sant\u00e9 Canada, plus\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/myeloma.ca\/fr\/2021\/05\/28\/pomalyst-pomalidomide-et-thalomid-thalidomide-evaluation-du-risque-potentiel-de-leucoencephalopathie-multifocale-progressive\/\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2021-05-28T05:00:00+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2025-08-19T13:28:17+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"POMALYST (POMALIDOMIDE) ET THALOMID (THALIDOMIDE) \u2013 \u00c9VALUATION DU RISQUE POTENTIEL DE LEUCOENC\u00c9PHALOPATHIE MULTIFOCALE PROGRESSIVE | My\u00e9lome Canada\" \/>\n\t\t<meta name=\"twitter:description\" content=\"Un r\u00e9sum\u00e9 de l\u2019examen de l\u2019innocuit\u00e9 (REI) concernant Pomalyst (pomalidomide) et Thalomid (thalidomide) et le risque potentiel de leucoenc\u00e9phalopathie multifocale progressive (LEMP) a \u00e9t\u00e9 publi\u00e9 par Sant\u00e9 Canada. Le but du REI est de permettre \u00e0 la population canadienne d\u2019avoir une compr\u00e9hension suffisante de l\u2019examen de l\u2019innocuit\u00e9 qui a \u00e9t\u00e9 men\u00e9 par Sant\u00e9 Canada, plus\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BlogPosting\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2021\\\/05\\\/28\\\/pomalyst-pomalidomide-et-thalomid-thalidomide-evaluation-du-risque-potentiel-de-leucoencephalopathie-multifocale-progressive\\\/#blogposting\",\"name\":\"POMALYST (POMALIDOMIDE) ET THALOMID (THALIDOMIDE) \\u2013 \\u00c9VALUATION DU RISQUE POTENTIEL DE LEUCOENC\\u00c9PHALOPATHIE MULTIFOCALE PROGRESSIVE | My\\u00e9lome Canada\",\"headline\":\"POMALYST (POMALIDOMIDE) ET THALOMID (THALIDOMIDE) &#8211; \\u00c9VALUATION DU RISQUE POTENTIEL DE LEUCOENC\\u00c9PHALOPATHIE MULTIFOCALE PROGRESSIVE\",\"author\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/stage.myeloma.ca\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo_en.png\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#articleImage\"},\"datePublished\":\"2021-05-28T00:00:00-05:00\",\"dateModified\":\"2025-08-19T08:28:17-05:00\",\"inLanguage\":\"fr-FR\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2021\\\/05\\\/28\\\/pomalyst-pomalidomide-et-thalomid-thalidomide-evaluation-du-risque-potentiel-de-leucoencephalopathie-multifocale-progressive\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2021\\\/05\\\/28\\\/pomalyst-pomalidomide-et-thalomid-thalidomide-evaluation-du-risque-potentiel-de-leucoencephalopathie-multifocale-progressive\\\/#webpage\"},\"articleSection\":\"Actualit\\u00e9s et \\u00e9v\\u00e9nement, Actualit\\u00e9s et \\u00e9v\\u00e9nement, Nouvelles de My\\u00e9lome Canada, Nouvelles de My\\u00e9lome Canada, Facultatif, Optional\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2021\\\/05\\\/28\\\/pomalyst-pomalidomide-et-thalomid-thalidomide-evaluation-du-risque-potentiel-de-leucoencephalopathie-multifocale-progressive\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#listItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/#listItem\",\"name\":\"Actualit\\u00e9s et \\u00e9v\\u00e9nement\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/#listItem\",\"position\":2,\"name\":\"Actualit\\u00e9s et \\u00e9v\\u00e9nement\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/nouvelles-de-myelome-canada\\\/#listItem\",\"name\":\"Nouvelles de My\\u00e9lome Canada\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#listItem\",\"name\":\"Accueil\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/nouvelles-de-myelome-canada\\\/#listItem\",\"position\":3,\"name\":\"Nouvelles de My\\u00e9lome Canada\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/nouvelles-de-myelome-canada\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2021\\\/05\\\/28\\\/pomalyst-pomalidomide-et-thalomid-thalidomide-evaluation-du-risque-potentiel-de-leucoencephalopathie-multifocale-progressive\\\/#listItem\",\"name\":\"POMALYST (POMALIDOMIDE) ET THALOMID (THALIDOMIDE) &#8211; \\u00c9VALUATION DU RISQUE POTENTIEL DE LEUCOENC\\u00c9PHALOPATHIE MULTIFOCALE PROGRESSIVE\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/#listItem\",\"name\":\"Actualit\\u00e9s et \\u00e9v\\u00e9nement\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2021\\\/05\\\/28\\\/pomalyst-pomalidomide-et-thalomid-thalidomide-evaluation-du-risque-potentiel-de-leucoencephalopathie-multifocale-progressive\\\/#listItem\",\"position\":4,\"name\":\"POMALYST (POMALIDOMIDE) ET THALOMID (THALIDOMIDE) &#8211; \\u00c9VALUATION DU RISQUE POTENTIEL DE LEUCOENC\\u00c9PHALOPATHIE MULTIFOCALE PROGRESSIVE\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/nouvelles-de-myelome-canada\\\/#listItem\",\"name\":\"Nouvelles de My\\u00e9lome Canada\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\",\"name\":\"Myeloma Canada\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"telephone\":\"+18887985771\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/stage.myeloma.ca\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo_en.png\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2021\\\/05\\\/28\\\/pomalyst-pomalidomide-et-thalomid-thalidomide-evaluation-du-risque-potentiel-de-leucoencephalopathie-multifocale-progressive\\\/#organizationLogo\"},\"image\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2021\\\/05\\\/28\\\/pomalyst-pomalidomide-et-thalomid-thalidomide-evaluation-du-risque-potentiel-de-leucoencephalopathie-multifocale-progressive\\\/#organizationLogo\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/\",\"name\":\"lemieuxbedard\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2021\\\/05\\\/28\\\/pomalyst-pomalidomide-et-thalomid-thalidomide-evaluation-du-risque-potentiel-de-leucoencephalopathie-multifocale-progressive\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/46bccf9afb319784ce7a4c49e51be67f2ed9bed19ab02f5f0a63c7aba8c80f06?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"lemieuxbedard\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2021\\\/05\\\/28\\\/pomalyst-pomalidomide-et-thalomid-thalidomide-evaluation-du-risque-potentiel-de-leucoencephalopathie-multifocale-progressive\\\/#webpage\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2021\\\/05\\\/28\\\/pomalyst-pomalidomide-et-thalomid-thalidomide-evaluation-du-risque-potentiel-de-leucoencephalopathie-multifocale-progressive\\\/\",\"name\":\"POMALYST (POMALIDOMIDE) ET THALOMID (THALIDOMIDE) \\u2013 \\u00c9VALUATION DU RISQUE POTENTIEL DE LEUCOENC\\u00c9PHALOPATHIE MULTIFOCALE PROGRESSIVE | My\\u00e9lome Canada\",\"description\":\"Un r\\u00e9sum\\u00e9 de l\\u2019examen de l\\u2019innocuit\\u00e9 (REI) concernant Pomalyst (pomalidomide) et Thalomid (thalidomide) et le risque potentiel de leucoenc\\u00e9phalopathie multifocale progressive (LEMP) a \\u00e9t\\u00e9 publi\\u00e9 par Sant\\u00e9 Canada. Le but du REI est de permettre \\u00e0 la population canadienne d\\u2019avoir une compr\\u00e9hension suffisante de l\\u2019examen de l\\u2019innocuit\\u00e9 qui a \\u00e9t\\u00e9 men\\u00e9 par Sant\\u00e9 Canada, plus\",\"inLanguage\":\"fr-FR\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2021\\\/05\\\/28\\\/pomalyst-pomalidomide-et-thalomid-thalidomide-evaluation-du-risque-potentiel-de-leucoencephalopathie-multifocale-progressive\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\"},\"datePublished\":\"2021-05-28T00:00:00-05:00\",\"dateModified\":\"2025-08-19T08:28:17-05:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"name\":\"Myeloma Canada\",\"inLanguage\":\"fr-FR\",\"publisher\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"POMALYST (POMALIDOMIDE) ET THALOMID (THALIDOMIDE) \u2013 \u00c9VALUATION DU RISQUE POTENTIEL DE LEUCOENC\u00c9PHALOPATHIE MULTIFOCALE PROGRESSIVE | My\u00e9lome Canada","description":"Un r\u00e9sum\u00e9 de l\u2019examen de l\u2019innocuit\u00e9 (REI) concernant Pomalyst (pomalidomide) et Thalomid (thalidomide) et le risque potentiel de leucoenc\u00e9phalopathie multifocale progressive (LEMP) a \u00e9t\u00e9 publi\u00e9 par Sant\u00e9 Canada. Le but du REI est de permettre \u00e0 la population canadienne d\u2019avoir une compr\u00e9hension suffisante de l\u2019examen de l\u2019innocuit\u00e9 qui a \u00e9t\u00e9 men\u00e9 par Sant\u00e9 Canada, plus","canonical_url":"https:\/\/myeloma.ca\/fr\/2021\/05\/28\/pomalyst-pomalidomide-et-thalomid-thalidomide-evaluation-du-risque-potentiel-de-leucoencephalopathie-multifocale-progressive\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"https:\/\/myeloma.ca\/fr\/2021\/05\/28\/pomalyst-pomalidomide-et-thalomid-thalidomide-evaluation-du-risque-potentiel-de-leucoencephalopathie-multifocale-progressive\/#blogposting","name":"POMALYST (POMALIDOMIDE) ET THALOMID (THALIDOMIDE) \u2013 \u00c9VALUATION DU RISQUE POTENTIEL DE LEUCOENC\u00c9PHALOPATHIE MULTIFOCALE PROGRESSIVE | My\u00e9lome Canada","headline":"POMALYST (POMALIDOMIDE) ET THALOMID (THALIDOMIDE) &#8211; \u00c9VALUATION DU RISQUE POTENTIEL DE LEUCOENC\u00c9PHALOPATHIE MULTIFOCALE PROGRESSIVE","author":{"@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author"},"publisher":{"@id":"https:\/\/myeloma.ca\/fr\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/stage.myeloma.ca\/wp-content\/uploads\/2023\/02\/logo_en.png","@id":"https:\/\/myeloma.ca\/fr\/#articleImage"},"datePublished":"2021-05-28T00:00:00-05:00","dateModified":"2025-08-19T08:28:17-05:00","inLanguage":"fr-FR","mainEntityOfPage":{"@id":"https:\/\/myeloma.ca\/fr\/2021\/05\/28\/pomalyst-pomalidomide-et-thalomid-thalidomide-evaluation-du-risque-potentiel-de-leucoencephalopathie-multifocale-progressive\/#webpage"},"isPartOf":{"@id":"https:\/\/myeloma.ca\/fr\/2021\/05\/28\/pomalyst-pomalidomide-et-thalomid-thalidomide-evaluation-du-risque-potentiel-de-leucoencephalopathie-multifocale-progressive\/#webpage"},"articleSection":"Actualit\u00e9s et \u00e9v\u00e9nement, Actualit\u00e9s et \u00e9v\u00e9nement, Nouvelles de My\u00e9lome Canada, Nouvelles de My\u00e9lome Canada, Facultatif, Optional"},{"@type":"BreadcrumbList","@id":"https:\/\/myeloma.ca\/fr\/2021\/05\/28\/pomalyst-pomalidomide-et-thalomid-thalidomide-evaluation-du-risque-potentiel-de-leucoencephalopathie-multifocale-progressive\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/#listItem","position":1,"name":"Accueil","item":"https:\/\/myeloma.ca\/fr\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/#listItem","name":"Actualit\u00e9s et \u00e9v\u00e9nement"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/#listItem","position":2,"name":"Actualit\u00e9s et \u00e9v\u00e9nement","item":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/nouvelles-de-myelome-canada\/#listItem","name":"Nouvelles de My\u00e9lome Canada"},"previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/#listItem","name":"Accueil"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/nouvelles-de-myelome-canada\/#listItem","position":3,"name":"Nouvelles de My\u00e9lome Canada","item":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/nouvelles-de-myelome-canada\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/2021\/05\/28\/pomalyst-pomalidomide-et-thalomid-thalidomide-evaluation-du-risque-potentiel-de-leucoencephalopathie-multifocale-progressive\/#listItem","name":"POMALYST (POMALIDOMIDE) ET THALOMID (THALIDOMIDE) &#8211; \u00c9VALUATION DU RISQUE POTENTIEL DE LEUCOENC\u00c9PHALOPATHIE MULTIFOCALE PROGRESSIVE"},"previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/#listItem","name":"Actualit\u00e9s et \u00e9v\u00e9nement"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/2021\/05\/28\/pomalyst-pomalidomide-et-thalomid-thalidomide-evaluation-du-risque-potentiel-de-leucoencephalopathie-multifocale-progressive\/#listItem","position":4,"name":"POMALYST (POMALIDOMIDE) ET THALOMID (THALIDOMIDE) &#8211; \u00c9VALUATION DU RISQUE POTENTIEL DE LEUCOENC\u00c9PHALOPATHIE MULTIFOCALE PROGRESSIVE","previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/nouvelles-de-myelome-canada\/#listItem","name":"Nouvelles de My\u00e9lome Canada"}}]},{"@type":"Organization","@id":"https:\/\/myeloma.ca\/fr\/#organization","name":"Myeloma Canada","url":"https:\/\/myeloma.ca\/fr\/","telephone":"+18887985771","logo":{"@type":"ImageObject","url":"https:\/\/stage.myeloma.ca\/wp-content\/uploads\/2023\/02\/logo_en.png","@id":"https:\/\/myeloma.ca\/fr\/2021\/05\/28\/pomalyst-pomalidomide-et-thalomid-thalidomide-evaluation-du-risque-potentiel-de-leucoencephalopathie-multifocale-progressive\/#organizationLogo"},"image":{"@id":"https:\/\/myeloma.ca\/fr\/2021\/05\/28\/pomalyst-pomalidomide-et-thalomid-thalidomide-evaluation-du-risque-potentiel-de-leucoencephalopathie-multifocale-progressive\/#organizationLogo"}},{"@type":"Person","@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author","url":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/","name":"lemieuxbedard","image":{"@type":"ImageObject","@id":"https:\/\/myeloma.ca\/fr\/2021\/05\/28\/pomalyst-pomalidomide-et-thalomid-thalidomide-evaluation-du-risque-potentiel-de-leucoencephalopathie-multifocale-progressive\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/46bccf9afb319784ce7a4c49e51be67f2ed9bed19ab02f5f0a63c7aba8c80f06?s=96&d=mm&r=g","width":96,"height":96,"caption":"lemieuxbedard"}},{"@type":"WebPage","@id":"https:\/\/myeloma.ca\/fr\/2021\/05\/28\/pomalyst-pomalidomide-et-thalomid-thalidomide-evaluation-du-risque-potentiel-de-leucoencephalopathie-multifocale-progressive\/#webpage","url":"https:\/\/myeloma.ca\/fr\/2021\/05\/28\/pomalyst-pomalidomide-et-thalomid-thalidomide-evaluation-du-risque-potentiel-de-leucoencephalopathie-multifocale-progressive\/","name":"POMALYST (POMALIDOMIDE) ET THALOMID (THALIDOMIDE) \u2013 \u00c9VALUATION DU RISQUE POTENTIEL DE LEUCOENC\u00c9PHALOPATHIE MULTIFOCALE PROGRESSIVE | My\u00e9lome Canada","description":"Un r\u00e9sum\u00e9 de l\u2019examen de l\u2019innocuit\u00e9 (REI) concernant Pomalyst (pomalidomide) et Thalomid (thalidomide) et le risque potentiel de leucoenc\u00e9phalopathie multifocale progressive (LEMP) a \u00e9t\u00e9 publi\u00e9 par Sant\u00e9 Canada. Le but du REI est de permettre \u00e0 la population canadienne d\u2019avoir une compr\u00e9hension suffisante de l\u2019examen de l\u2019innocuit\u00e9 qui a \u00e9t\u00e9 men\u00e9 par Sant\u00e9 Canada, plus","inLanguage":"fr-FR","isPartOf":{"@id":"https:\/\/myeloma.ca\/fr\/#website"},"breadcrumb":{"@id":"https:\/\/myeloma.ca\/fr\/2021\/05\/28\/pomalyst-pomalidomide-et-thalomid-thalidomide-evaluation-du-risque-potentiel-de-leucoencephalopathie-multifocale-progressive\/#breadcrumblist"},"author":{"@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author"},"creator":{"@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author"},"datePublished":"2021-05-28T00:00:00-05:00","dateModified":"2025-08-19T08:28:17-05:00"},{"@type":"WebSite","@id":"https:\/\/myeloma.ca\/fr\/#website","url":"https:\/\/myeloma.ca\/fr\/","name":"Myeloma Canada","inLanguage":"fr-FR","publisher":{"@id":"https:\/\/myeloma.ca\/fr\/#organization"}}]},"og:locale":"fr_FR","og:site_name":"My\u00e9lome Canada |","og:type":"article","og:title":"POMALYST (POMALIDOMIDE) ET THALOMID (THALIDOMIDE) \u2013 \u00c9VALUATION DU RISQUE POTENTIEL DE LEUCOENC\u00c9PHALOPATHIE MULTIFOCALE PROGRESSIVE | My\u00e9lome Canada","og:description":"Un r\u00e9sum\u00e9 de l\u2019examen de l\u2019innocuit\u00e9 (REI) concernant Pomalyst (pomalidomide) et Thalomid (thalidomide) et le risque potentiel de leucoenc\u00e9phalopathie multifocale progressive (LEMP) a \u00e9t\u00e9 publi\u00e9 par Sant\u00e9 Canada. Le but du REI est de permettre \u00e0 la population canadienne d\u2019avoir une compr\u00e9hension suffisante de l\u2019examen de l\u2019innocuit\u00e9 qui a \u00e9t\u00e9 men\u00e9 par Sant\u00e9 Canada, plus","og:url":"https:\/\/myeloma.ca\/fr\/2021\/05\/28\/pomalyst-pomalidomide-et-thalomid-thalidomide-evaluation-du-risque-potentiel-de-leucoencephalopathie-multifocale-progressive\/","article:published_time":"2021-05-28T05:00:00+00:00","article:modified_time":"2025-08-19T13:28:17+00:00","twitter:card":"summary_large_image","twitter:title":"POMALYST (POMALIDOMIDE) ET THALOMID (THALIDOMIDE) \u2013 \u00c9VALUATION DU RISQUE POTENTIEL DE LEUCOENC\u00c9PHALOPATHIE MULTIFOCALE PROGRESSIVE | My\u00e9lome Canada","twitter:description":"Un r\u00e9sum\u00e9 de l\u2019examen de l\u2019innocuit\u00e9 (REI) concernant Pomalyst (pomalidomide) et Thalomid (thalidomide) et le risque potentiel de leucoenc\u00e9phalopathie multifocale progressive (LEMP) a \u00e9t\u00e9 publi\u00e9 par Sant\u00e9 Canada. Le but du REI est de permettre \u00e0 la population canadienne d\u2019avoir une compr\u00e9hension suffisante de l\u2019examen de l\u2019innocuit\u00e9 qui a \u00e9t\u00e9 men\u00e9 par Sant\u00e9 Canada, plus"},"aioseo_meta_data":{"post_id":"11192","title":null,"description":null,"keywords":null,"keyphrases":null,"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":null,"og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":null,"robots_max_videopreview":null,"robots_max_imagepreview":"large","priority":null,"frequency":null,"local_seo":null,"breadcrumb_settings":null,"limit_modified_date":false,"ai":null,"created":"2023-09-18 16:57:14","updated":"2026-04-30 07:19:04","seo_analyzer_scan_date":null,"focus_keyword":null,"additional_keywords":null,"truseo_locale":null},"_links":{"self":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11192","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/comments?post=11192"}],"version-history":[{"count":1,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11192\/revisions"}],"predecessor-version":[{"id":31299,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11192\/revisions\/31299"}],"wp:attachment":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/media?parent=11192"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/categories?post=11192"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/tags?post=11192"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}